Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Fortrea (FTRE) stock in plain English

Free brief · no signupStart here
FTREPublished Nov 17, 2026
Fortrea Holdings Inc
Healthcare · Biotechnology
Provides clinical trial management, patient recruitment, and regulatory consulting services for pharmaceutical companies.
Assets:
90+ countriesmanages clinical study sites and trials globally
11,000+ employeesclinical research professionals and study coordinators
Phase I research unitsdedicated inpatient beds for early human drug studies
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

22
OPS ScoreOperating finances
Latest quote
-1.71%$20.15
$1.94B
n/a (loss)
$2.66B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was FTRE. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Fortrea (FTRE) do?

Fortrea Holdings Inc (FTRE) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Provides clinical trial management, patient recruitment, and regulatory consulting services for pharmaceutical companies. Manages phase one through four clinical drug trials globally for pharmaceutical and biotechnology sponsors. It is worth $1.94B on the market and sold $2.66B over the last year.

Market cap
$1.94B
P/E ratio
None (reported a loss)
Annual sales
$2.66B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 17, 2026

FTRE’s flags, in plain English

Each flag is a number from Fortrea’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Cheap on Cash Flow

Priced at 11.5 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Debt Is Driving

Heavy debt, 210% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about FTRE

How big is Fortrea?

Fortrea’s market cap is $1.94B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.66B: what customers paid the company over the last year, before any costs.

What is FTRE’s P/E ratio?

FTRE has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with FTRE?

A large share of total revenue depends on clinical trial spending by biotechnology companies that face tight financing conditions. That is one risk on Fortrea’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Fortrea’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. FTRE’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card